Browse NFASC

Summary
SymbolNFASC
Nameneurofascin
Aliases NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type I membrane protein.
Domain PF13882 Bravo-like intracellular region
PF00041 Fibronectin type III domain
PF07679 Immunoglobulin I-set domain
PF00047 Immunoglobulin domain
Function

Cell adhesion, ankyrin-binding protein which may be involved in neurite extension, axonal guidance, synaptogenesis, myelination and neuron-glial cell interactions.

> Gene Ontology
 
Biological Process GO:0002175 protein localization to paranode region of axon
GO:0006612 protein targeting to membrane
GO:0007009 plasma membrane organization
GO:0007043 cell-cell junction assembly
GO:0007272 ensheathment of neurons
GO:0007409 axonogenesis
GO:0007411 axon guidance
GO:0007422 peripheral nervous system development
GO:0008366 axon ensheathment
GO:0010927 cellular component assembly involved in morphogenesis
GO:0019226 transmission of nerve impulse
GO:0021700 developmental maturation
GO:0030913 paranodal junction assembly
GO:0032288 myelin assembly
GO:0034113 heterotypic cell-cell adhesion
GO:0034329 cell junction assembly
GO:0034330 cell junction organization
GO:0035637 multicellular organismal signaling
GO:0042551 neuron maturation
GO:0042552 myelination
GO:0045161 neuronal ion channel clustering
GO:0045162 clustering of voltage-gated sodium channels
GO:0045216 cell-cell junction organization
GO:0048469 cell maturation
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0050808 synapse organization
GO:0061564 axon development
GO:0071205 protein localization to juxtaparanode region of axon
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0072661 protein targeting to plasma membrane
GO:0090002 establishment of protein localization to plasma membrane
GO:0090150 establishment of protein localization to membrane
GO:0097485 neuron projection guidance
GO:0099612 protein localization to axon
GO:1990778 protein localization to cell periphery
Molecular Function GO:0086080 protein binding involved in heterotypic cell-cell adhesion
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
Cellular Component GO:0005902 microvillus
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
GO:0030424 axon
GO:0033010 paranodal junction
GO:0033267 axon part
GO:0033268 node of Ranvier
GO:0033270 paranode region of axon
GO:0043194 axon initial segment
GO:0043209 myelin sheath
GO:0044304 main axon
GO:0097386 glial cell projection
GO:0097454 Schwann cell microvillus
GO:0098858 actin-based cell projection
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
Reactome R-HSA-422475: Axon guidance
R-HSA-1266738: Developmental Biology
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-445095: Interaction between L1 and Ankyrins
R-HSA-373760: L1CAM interactions
R-HSA-447043: Neurofascin interactions
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolNFASC
Nameneurofascin
Aliases NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NFASC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolNFASC
Nameneurofascin
Aliases NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NFASC in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNFASC
Nameneurofascin
Aliases NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NFASC in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2570.673
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0310.977
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4660.6
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3480.387
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1740.938
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5590.831
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.4460.00923
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.6410.115
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.3610.192
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4140.674
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2660.313
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1410.392
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NFASC in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.14.170.339
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.15.160.373
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21171923.5-4.51
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.436.4-210.357
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.97.40.51
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNFASC
Nameneurofascin
Aliases NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NFASC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNFASC
Nameneurofascin
Aliases NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NFASC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NFASC.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNFASC
Nameneurofascin
Aliases NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NFASC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNFASC
Nameneurofascin
Aliases NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NFASC expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNFASC
Nameneurofascin
Aliases NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NFASC and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNFASC
Nameneurofascin
Aliases NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NFASC collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.